Yoke Seng Lee

Yoke Seng Lee

Auto-generated profile, based on publicly available information

Yoke Seng Lee

Division of Hematology, Brigham and Women's Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2015 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MCMeng‐Chieh Chiang
Meng‐Chieh Chiang
KTKirsteen M. Tullett
Kirsteen M. Tullett
YLYoke Seng Lee
Yoke Seng Lee
Adi IdrisAdi Idris
Adi Idris
YDYitian Ding
Yitian Ding
KRKristen Radford
Kristen Radford

11 May 2023 in Blood
Verified
Journal Article
Open access
PDF file
YLYoke Seng Lee
Yoke Seng Lee
PGPeter van Galen
Peter van Galen
In this issue of Blood, Diamond et al reconstruct clonal trajectories that lead to therapy-related myeloid neoplasms (tMNs), showing emergence from preexisting

5 February 2026 in Blood Neoplasia
Verified
Journal Article
Open access
YLYoke Seng Lee
Yoke Seng Lee
JGJonathan D. Good
Jonathan D. Good
NANoha Awais
Noha Awais
BEBenjamin K. Eschle
Benjamin K. Eschle
MLMaia S. Lineberry
Maia S. Lineberry
PGPeter van Galen
Peter van Galen
• The eIF4A inhibitor zotatifin with the BCL-2 inhibitor venetoclax is a promising combination therapy for AML.

31 January 2020
Verified
Thesis
Closed access
YLYoke Seng Lee
Yoke Seng Lee
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

22 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYoke Seng Lee
Yoke Seng Lee
JGJonathan D. Good
Jonathan D. Good
NANoha Awais
Noha Awais
BEBenjamin K. Eschle
Benjamin K. Eschle
MLMaia S. Lineberry
Maia S. Lineberry
PGPeter van Galen
Peter van Galen
Targeted therapies like Venetoclax have increased the options available to acute myeloid leukemia (AML) patients, but survival remains poor due to drug resistance and disease relapse. We found that the translation initiation factor EIF4A1, which unwinds complex mRNA structures in the 5' UTR of oncogenic transcripts, is highly expressed in AML stem- and progenitor-like cells. Inhibiting eIF4A with the small molecule Zotatifin reduces translation of transcripts related to the cell cycle and survival. This results in downregulation of AKT, STAT-5, and MCL-1 and underlies synergy of Zotatifin with Venetoclax. The drug combination promotes apoptosis across AML genotypes, while the effect on healthy blood cells is limited. Using in vivo relapsed and refractory AML patient-derived xenograft models, the combination significantly suppressed tumor burden and prolonged survival of xenografted mice. These results support eIF4A-mediated protein translation as a therapeutic target in AML.